- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
II
Principal Investigator(s)
Beatrice Chen
Objective
This study will evaluate the safety of the dapivirine vaginal ring when inserted once every 4 weeks in postmenopausal women for 12 weeks of product use.
Last updated May 16, 2021
Prevention Option(s)
Microbicides
Study Design
Randomized
Double-blind
Arms and Assigned Interventions
Mode of Delivery
Ring
Products
Dapivirine Ring
ARMs
Experimental
Description
Placebo ring
Mode of Delivery
Ring
ARMs
Placebo Comparator
Official Code
Trial Sponsors
International Partnership for Microbicides, Inc., MTN
December 2013
May 2014
Enrollment
96
45
Years
65
Years
Population
Women
Sites
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania
United States of America
University of Alabama at Birmingham
Birmingham, Alabama
United States of America
Case Western Reserve University/University Hospitals Case Medical Center
Clevelan, Ohio
United States of America